Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Livzon Pharmaceutical Group ( (HK:1513) ) just unveiled an announcement.
Livzon Pharmaceutical Group has amended the terms of its planned acquisition of a controlling stake in Vietnam’s Imexpharm Corporation, extending the deadline for completion to 30 June 2026 and clarifying merger control conditions to ensure regulatory compliance. With all conditions precedent now satisfied, the company’s board has approved an intended public tender offer to all Imexpharm shareholders, lifting the maximum potential consideration to approximately VND6.89 trillion (about RMB1.846 billion). As the deal now triggers a mandatory tender offer under Vietnamese securities rules, it will proceed as a discloseable transaction under Hong Kong Listing Rules without requiring independent shareholder approval, marking a significant step in Livzon’s push to deepen its presence in the Vietnamese pharmaceutical market, subject to final clearance by Vietnamese regulators.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a Hong Kong-listed pharmaceutical company engaged in the development, manufacturing and sale of pharmaceutical products, with a strategic focus on expanding its presence in overseas markets, including Southeast Asia. The group uses mergers and acquisitions and equity investments to strengthen its regional footprint and enhance access to local drug distribution and manufacturing capabilities.
Average Trading Volume: 735,449
Technical Sentiment Signal: Hold
Current Market Cap: HK$32.19B
Find detailed analytics on 1513 stock on TipRanks’ Stock Analysis page.